Public Employees Retirement System of Ohio Decreases Stock Holdings in Gilead Sciences, Inc. $GILD

Public Employees Retirement System of Ohio reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 565,802 shares of the biopharmaceutical company’s stock after selling 17,326 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Gilead Sciences were worth $78,856,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Compound Planning Inc. increased its position in shares of Gilead Sciences by 8.2% during the 1st quarter. Compound Planning Inc. now owns 39,125 shares of the biopharmaceutical company’s stock valued at $5,453,000 after purchasing an additional 2,977 shares during the last quarter. Klingman & Associates LLC raised its stake in shares of Gilead Sciences by 4.7% during the 1st quarter. Klingman & Associates LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 119 shares during the period. Modern Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 12.4% in the 1st quarter. Modern Wealth Management LLC now owns 10,592 shares of the biopharmaceutical company’s stock worth $1,486,000 after buying an additional 1,170 shares during the last quarter. Keebeck Wealth Management boosted its holdings in shares of Gilead Sciences by 27.1% in the 1st quarter. Keebeck Wealth Management now owns 4,185 shares of the biopharmaceutical company’s stock worth $583,000 after buying an additional 893 shares during the last quarter. Finally, Orleans Capital Management Corp LA grew its position in Gilead Sciences by 2.3% during the first quarter. Orleans Capital Management Corp LA now owns 10,852 shares of the biopharmaceutical company’s stock valued at $1,512,000 after buying an additional 248 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the sale, the chief executive officer owned 607,133 shares in the company, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 77,000 shares of company stock worth $9,978,740. Corporate insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GILD. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Morgan Stanley reduced their target price on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a report on Monday, July 6th. Rothschild & Co Redburn dropped their price objective on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Finally, Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $158.33.

Gilead Sciences Price Performance

NASDAQ GILD opened at $130.86 on Friday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a market cap of $162.47 billion, a PE ratio of 17.83 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The firm’s 50-day simple moving average is $129.55 and its two-hundred day simple moving average is $135.54.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter last year, the company earned $1.81 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts predict that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.